You are here: Industry Insights > DME

News List

FDA accepts application for Roche’s Faricimab expresspharma
July 30, 2021
If approved, Faricimab would be the first and only medicine designed to target two distinct pathways that drive retinal diseases that can cause vision loss.
Roche’s vision loss therapy faricimab extends time between treatments by up to four months pharmatimes
February 20, 2021
Roche’s investigational bispecific antibody faricimab has been found to extend the time between treatments by up to four months in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).
Roche’s faricimab hits the mark in diabetic macular edema study pharmatimes
December 22, 2020
Swiss pharma company Roche has announced that its investigational bispecific antibody faricimab met the primary endpoint across two phase III studies in diabetic macular edema (DME), a leading cause of vision loss.
Novartis Reports Positive Topline Results from Beovu for Diabetic Macular Edema americanpharmaceuticalreview
September 21, 2020
Novartis reported the first interpretable results of the Phase III KITE study, assessing the efficacy and safety of Beovu® (brolucizumab) 6 mg in diabetic macular edema (DME).
Kodiak Sciences Receives Positive Phase I Data contractpharma
July 31, 2019
Phase 1b study complete for KSI-301, treatment of (wet) AMD, DME, and RVO.
RetiPharma Secures Funding to Develop Treatments of Degenerative Eye Disorders pharmafile
November 12, 2018
RetiPharma, focusing on the development of products for the treatment of degenerative eye disorders based on an in vivo platform for translation from in vivo models to humans
SemaThera announces licensing deal for China, Japan biospectrumasia
March 26, 2018
As part of this financing, SemaThera also signed an exclusive option of license with Senju.